Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Anthracycline-induced cardiomyopathy.

N G Fisher¹, A J Marshall

¹South West Cardiothoracic Unit, Derriford Hospital, Plymouth, Devon, UK.

Postgraduate Medical Journal

|October 26, 1999

Summary

Anthracycline cardiomyopathy is decreasing due to dose limits, but persists in sensitive patients. Angiotensin-converting enzyme inhibitors show benefit, and antioxidants warrant further study for prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.

Cell death & disease·2014

Same author

Follicular dendritic cell secreted protein FDC-SP controls IgA production.

Mucosal immunology·2014

Same author

Haemoglobin levels in blood donors.

Glasgow medical journal·2010

Same author

Atenolol-Once-daily Dosage.

Proceedings of the Royal Society of Medicine·2010

Same author

Epidermal and dermal integration into sphere-templated porous poly(2-hydroxyethyl methacrylate) implants in mice.

Journal of biomedical materials research. Part A·2010

Same author

Evaluating orangutan census techniques using nest decay rates: implications for population estimates.

Ecological applications : a publication of the Ecological Society of America·2008

Area of Science:

Cardiology
Oncology
Pharmacology

Background:

Anthracycline chemotherapy can cause cardiomyopathy, a serious side effect.
Modern protocols have reduced its incidence through dose management and monitoring.

Observation:

Despite advancements, anthracycline-induced cardiomyopathy remains a concern for specific patient groups requiring high doses.
Individual patient sensitivity necessitates ongoing vigilance.

Findings:

Angiotensin-converting enzyme (ACE) inhibitor therapy has demonstrated clear benefits in managing or preventing anthracycline cardiomyopathy.
Antioxidant therapies, including probucol and vitamins, show potential but require further clinical investigation.

Implications:

Early introduction of ACE inhibitors is recommended to mitigate cardiac risks.
Further research into antioxidant interventions could significantly lower the future incidence of this chemotherapy-related heart condition.

Related Experiment Videos